R

Ryvu Therapeutics SA
WSE:RVU

Watchlist Manager
Ryvu Therapeutics SA
WSE:RVU
Watchlist
Price: 39 PLN -1.27% Market Closed
Market Cap: 901.7m PLN
Have any thoughts about
Ryvu Therapeutics SA?
Write Note

Ryvu Therapeutics SA
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ryvu Therapeutics SA
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
R
Ryvu Therapeutics SA
WSE:RVU
Cash from Operating Activities
-zł121m
CAGR 3-Years
-28%
CAGR 5-Years
-26%
CAGR 10-Years
-35%
I
Inno-Gene SA
WSE:IGN
Cash from Operating Activities
-zł948k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
9%
M
Medicofarma Biotech SA
WSE:MDB
Cash from Operating Activities
zł4.8k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Selvita SA
WSE:SLV
Cash from Operating Activities
zł76.7m
CAGR 3-Years
18%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Ryvu Therapeutics SA
Glance View

Market Cap
901.5m PLN
Industry
Life Sciences Tools & Services

Ryvu Therapeutics SA engages in the provision of products and solutions for the pharmaceutical and biotechnology industry. The company is headquartered in Krakow, Woj. Malopolskie and currently employs 186 full-time employees. The company went IPO on 2011-07-14. The firm is active in the pharmaceutical and biotechnology fields. The company operates through two business segments. The Innovative segment develops new drugs mainly for oncology and central nervous system diseases. The Services segment is engaged in the research and development activities, such as introducing substances on the market, client service and reducing the risk. The Company’s portfolio encompasses projects, including kinesis inhibitors platform, the platform of the metabolism for the cancer and epigenetic, among others. Ryvu Therapeutics SA is active in the domestic market and internationally, such as in the United States. The company operates through unit Ardigen SA and SORS Holdings Ltd.

RVU Intrinsic Value
42.31 PLN
Undervaluation 8%
Intrinsic Value
Price
R

See Also

What is Ryvu Therapeutics SA's Cash from Operating Activities?
Cash from Operating Activities
-121m PLN

Based on the financial report for Sep 30, 2024, Ryvu Therapeutics SA's Cash from Operating Activities amounts to -121m PLN.

What is Ryvu Therapeutics SA's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-35%

Over the last year, the Cash from Operating Activities growth was -2 253%. The average annual Cash from Operating Activities growth rates for Ryvu Therapeutics SA have been -28% over the past three years , -26% over the past five years , and -35% over the past ten years .

Back to Top